People: Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

14 Jul 2020
Change (% chg)

$0.00 (-0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Gasmi, Mehdi 

Dr. Mehdi Gasmi Ph.D. serves as Director of the Company. Dr. Gasmi served as our president and chief scientific officer since October 2018. From February 2017, to October 2018, he served as our chief science and technology officer. Previously, he served as our interim chief scientific officer from July 2015 to February 2018, senior vice president, pharmaceutical development from May 2015 to July 2015, and as vice president, pharmaceutical development from November 2013 to May 2015. From December 2011 to November 2013, as principal of ClinVec Solutions, LLC, Dr. Gasmi provided adeno-associated virus (“AAV”) and lentiviral gene therapy consulting services to various companies, including to us, from June 2013 to October 2013. Prior to that, Dr. Gasmi oversaw production of clinical batches of recombinant AAV and lentiviral gene therapy products for both Genethon, a nonprofit gene therapy company, where he served as vice president of biomanufacturing from July 2009 to December 2011, and for Ceregene, a gene therapy company, where he served as senior director, product development from December 2001 to June 2009. Dr. Gasmi obtained his M.S. and his Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 106,379
Fiscal Year Total, USD 106,379

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --